{"id":617578,"date":"2022-09-20T20:32:01","date_gmt":"2022-09-20T20:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=617578"},"modified":"2022-09-20T20:32:01","modified_gmt":"2022-09-20T20:32:01","slug":"parkinsons-disease-therapeutic-pipeline-analysis-insights-into-the-latest-fda-and-ema-approvals-clinical-trials-and-treatment-algorithm-amneal-ipx203-pharma-two-b-p2b001-annovis-bio","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/parkinsons-disease-therapeutic-pipeline-analysis-insights-into-the-latest-fda-and-ema-approvals-clinical-trials-and-treatment-algorithm-amneal-ipx203-pharma-two-b-p2b001-annovis-bio_617578.html","title":{"rendered":"Parkinson’s Disease Therapeutic Pipeline Analysis | Insights into the Latest FDA and EMA Approvals, Clinical Trials, and Treatment Algorithm | Amneal (IPX203), Pharma Two B (P2B001), Annovis Bio"},"content":{"rendered":"
\n
\"Parkinson's<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight\u2019s assessment, globally, about 140+ key pharma and biotech companies are working on 150+ pipeline drugs in the Parkinson’s Disease therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n

Parkinson’s Disease Market Size is anticipated to register immense growth in the coming years owing to a better understanding of the disease, emerging pipeline, and gene and stem therapies development.<\/em><\/p>\n

“Parkinson’s Disease Pipeline Insight, 2022<\/strong>” report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the  Parkinson’s Disease Market. <\/p>\n

The Parkinson’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. <\/p>\n

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n

\"Parkinson's<\/p>\n

Parkinson’s Disease Pipeline Analysis<\/strong><\/a><\/p>\n

The report provides insights into:<\/strong> <\/p>\n